Altimmune Inc (ALT)

$3.08 -0.01 (-0.32%)
Market Cap 402.02M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.15
Volume 2,424,900
Avg Vol 4,269,692
Day's Range N/A - N/A
Shares Out 130.11M
Stochastic %K 74%
Beta 0.18
Analysts Strong Sell
Price Target $18.15

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
SBL71
SBL71 May. 13 at 11:48 AM
$ALT FK u Jerry! Sometime in second half.
0 · Reply
FSDPSK
FSDPSK May. 13 at 11:47 AM
$ALT 🧠 Some fools don’t even understand how a trial works 😆 And imagine expecting a 52wk readout in early 2028. Jesus fucking christ, you’re talking about Phase 3, you stupid assholes 🤣 Initiation alone will take 18-24 months - that’s why the company explicitly said the readout is expected in 2H 2029. And that’s the absolute EARLIEST they can announce it. If there are any delays during initiation, that date is getting pushed even further back. It looks like they chose to GIA. Keep dreaming while your bags getting heavier 😂😂😂
1 · Reply
Babybock
Babybock May. 13 at 11:46 AM
$ALT well damn I feel like it is going to be a good day in ALT world. Very very
0 · Reply
Corpkcots
Corpkcots May. 13 at 11:40 AM
$ALT
0 · Reply
TradeSun
TradeSun May. 13 at 11:40 AM
$ALT https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2026-financial-results-and
0 · Reply
Turribull
Turribull May. 13 at 11:40 AM
$ALT As for me, I actually liked a business update for the first time in a year. 😈
0 · Reply
SeeingGreen420
SeeingGreen420 May. 13 at 11:40 AM
$ALT so it’s gonna be a 52 week mash phase 3 trial starting second half of 2026!! So finish at end of 2027 and results by early early 2028 at the latest maybe even end of 2027, there is no 2029 readout anyone sharing that is a false FUD spreader
4 · Reply
Benji596
Benji596 May. 13 at 11:40 AM
$ALT ALD enrollment to complete Q3
0 · Reply
Wolly99
Wolly99 May. 13 at 11:39 AM
$ALT Phase 3 finalized and ready to go. Awesome. I think there was some nervousness that they would old off until a partnership, like SGMT is doing. This is great though!
0 · Reply
Benji596
Benji596 May. 13 at 11:38 AM
$ALT EMA alignment
0 · Reply
Latest News on ALT
Altimmune Announces First Quarter 2026 Financial Results and Business Update

May 13, 2026, 7:30 AM EDT - 19 minutes ago

Altimmune Announces First Quarter 2026 Financial Results and Business Update

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

May 13, 2026, 7:15 AM EDT - 34 minutes ago

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

May 6, 2026, 7:30 AM EDT - 7 days ago

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

Altimmune management to meet with Piper Sandler

2026-04-27T19:56:05.000Z - 15 days ago

Altimmune management to meet with Piper Sandler

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Apr 27, 2026, 7:00 AM EDT - 16 days ago

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-24T09:16:13.000Z - 19 days ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs

Altimmune 64.25M share Spot Secondary priced at $3.00

2026-04-23T11:06:36.000Z - 20 days ago

Altimmune 64.25M share Spot Secondary priced at $3.00

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Apr 22, 2026, 11:25 PM EDT - 20 days ago

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

Altimmune announces common stock offering, no amount given

2026-04-22T20:28:30.000Z - 20 days ago

Altimmune announces common stock offering, no amount given

Altimmune Announces Proposed Underwritten Public Offering of Securities

Apr 22, 2026, 4:19 PM EDT - 20 days ago

Altimmune Announces Proposed Underwritten Public Offering of Securities

Altimmune Transcript: AGM 2026

Apr 16, 2026, 8:30 AM EDT - 26 days ago

Altimmune Transcript: AGM 2026

Altimmune initiated with a Buy at Truist

2026-03-18T20:00:19.000Z - 7 weeks ago

Altimmune initiated with a Buy at Truist

Altimmune price target raised to $25 from $12 at H.C. Wainwright

2026-03-16T16:15:11.000Z - 2 months ago

Altimmune price target raised to $25 from $12 at H.C. Wainwright

Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 10:30 AM EDT - 2 months ago

Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference

Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 2 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026

Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:15 PM EDT - 2 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026

Altimmune price target lowered to $13 from $18 at B. Riley

2026-03-06T13:40:07.000Z - 2 months ago

Altimmune price target lowered to $13 from $18 at B. Riley

Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 2 months ago

Altimmune Earnings Call Transcript: Q4 2025

Altimmune reports Q4 EPS (27c), consensus (24c)

2026-03-05T12:14:56.000Z - 2 months ago

Altimmune reports Q4 EPS (27c), consensus (24c)

Options Volatility and Implied Earnings Moves Today, March 05, 2026

2026-03-05T12:05:26.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 05, 2026

CIEN COST GPRO KR LCTX MRVL PBR

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Mar 5, 2026, 7:00 AM EST - 2 months ago

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Altimmune to Participate in Upcoming Investor Conferences

Mar 2, 2026, 7:30 AM EST - 2 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Feb 26, 2026, 7:30 AM EST - 2 months ago

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Altimmune management to meet with Piper Sandler

2026-02-20T14:12:05.000Z - 2 months ago

Altimmune management to meet with Piper Sandler

Altimmune initiated with a Buy at Titan Partners

2026-02-13T14:55:31.000Z - 3 months ago

Altimmune initiated with a Buy at Titan Partners

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 3 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 29, 2026, 5:54 PM EST - 3 months ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

2026-01-28T08:09:07.000Z - 3 months ago

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

LLY NVO

Altimmune prices $75M registered direct offering

2026-01-28T05:35:22.000Z - 3 months ago

Altimmune prices $75M registered direct offering

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 3 months ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Altimmune initiated with an Overweight at Barclays

2026-01-27T21:27:07.000Z - 3 months ago

Altimmune initiated with an Overweight at Barclays

Altimmune initiated with an Overweight at Barclays

2026-01-27T21:16:41.000Z - 3 months ago

Altimmune initiated with an Overweight at Barclays

Altimmune call volume above normal and directionally bullish

2026-01-22T20:45:16.000Z - 3 months ago

Altimmune call volume above normal and directionally bullish

Unusually active option classes on open January 22nd

2026-01-22T14:40:28.000Z - 3 months ago

Unusually active option classes on open January 22nd

ANET BARK FNKO GE JBLU LAES OMEX

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 4 months ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 5 months ago

Altimmune Transcript: Study Result

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 5 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 5 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 2:30 PM EST - 5 months ago

Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 5 months ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 5 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 3:00 AM EST - 6 months ago

Altimmune Transcript: Jefferies London Healthcare Conference 2025

Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 6 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 6 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 6 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Altimmune Earnings Call Transcript: Q3 2025

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 6 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 6 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 6 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 21, 2025, 7:00 AM EDT - 7 months ago

Altimmune Transcript: H.C. Wainwright Liver Disease Virtual Conference

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 7 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:30 AM EDT - 8 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 8 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Altimmune Transcript: AGM 2025

Sep 25, 2025, 8:30 AM EDT - 8 months ago

Altimmune Transcript: AGM 2025

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 8 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:45 AM EDT - 8 months ago

Altimmune Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Altimmune Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Altimmune Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 9 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 9 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

SBL71
SBL71 May. 13 at 11:48 AM
$ALT FK u Jerry! Sometime in second half.
0 · Reply
FSDPSK
FSDPSK May. 13 at 11:47 AM
$ALT 🧠 Some fools don’t even understand how a trial works 😆 And imagine expecting a 52wk readout in early 2028. Jesus fucking christ, you’re talking about Phase 3, you stupid assholes 🤣 Initiation alone will take 18-24 months - that’s why the company explicitly said the readout is expected in 2H 2029. And that’s the absolute EARLIEST they can announce it. If there are any delays during initiation, that date is getting pushed even further back. It looks like they chose to GIA. Keep dreaming while your bags getting heavier 😂😂😂
1 · Reply
Babybock
Babybock May. 13 at 11:46 AM
$ALT well damn I feel like it is going to be a good day in ALT world. Very very
0 · Reply
Corpkcots
Corpkcots May. 13 at 11:40 AM
$ALT
0 · Reply
TradeSun
TradeSun May. 13 at 11:40 AM
$ALT https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2026-financial-results-and
0 · Reply
Turribull
Turribull May. 13 at 11:40 AM
$ALT As for me, I actually liked a business update for the first time in a year. 😈
0 · Reply
SeeingGreen420
SeeingGreen420 May. 13 at 11:40 AM
$ALT so it’s gonna be a 52 week mash phase 3 trial starting second half of 2026!! So finish at end of 2027 and results by early early 2028 at the latest maybe even end of 2027, there is no 2029 readout anyone sharing that is a false FUD spreader
4 · Reply
Benji596
Benji596 May. 13 at 11:40 AM
$ALT ALD enrollment to complete Q3
0 · Reply
Wolly99
Wolly99 May. 13 at 11:39 AM
$ALT Phase 3 finalized and ready to go. Awesome. I think there was some nervousness that they would old off until a partnership, like SGMT is doing. This is great though!
0 · Reply
Benji596
Benji596 May. 13 at 11:38 AM
$ALT EMA alignment
0 · Reply
Mr_Pean
Mr_Pean May. 13 at 11:36 AM
$ALT data readout for mash P3 in 2029??? Please tell me that I’m just tired and misreading this. “The Company expects to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data readout anticipated in 2029” WTF how does a 1 year trial take that long???
4 · Reply
Bee_ST
Bee_ST May. 13 at 11:35 AM
$ALT * Best of EASL * Late Breaker * finalized P3 protocol * FDA + EMA alignment * $535M cash * institutional takeover of Ownership
2 · Reply
ViperV22
ViperV22 May. 13 at 11:33 AM
$ALT
0 · Reply
Groggok
Groggok May. 13 at 11:33 AM
$ALT https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2026-financial-results-and
0 · Reply
Corpkcots
Corpkcots May. 13 at 11:33 AM
$ALT
0 · Reply
Turribull
Turribull May. 13 at 11:32 AM
$ALT
1 · Reply
Turribull
Turribull May. 13 at 11:31 AM
$ALT there it is.
0 · Reply
jayessbee
jayessbee May. 13 at 11:28 AM
$ALT https://www.statnews.com/2026/05/12/america-alcohol-epidemic-plain-sight-deadliest-drug-series-part-1/
0 · Reply
Bee_ST
Bee_ST May. 13 at 11:27 AM
$ALT Best of EASL!!!
1 · Reply
Diapers_Tequila
Diapers_Tequila May. 13 at 11:26 AM
$ALT We have plans for the one year anniversary of 6/26 yet?
2 · Reply
CrappieDude
CrappieDude May. 13 at 11:22 AM
$ALT “The company also announced that its abstract on 48-week results has been selected by EASL as Best of EASL 2026 in their summary deck for its noteworthy contribution to the scientific program of the EASL congress.”
1 · Reply
TradeSun
TradeSun May. 13 at 11:22 AM
$ALT "The company also announced that its abstract on 48-week results has been selected by EASL as Best of EASL 2026 in their summary deck for its noteworthy contribution to the scientific program of the EASL congress."
0 · Reply